Artificial Intelligence in Cancer Diagnostics Market Size - Share Outlook, Growth Analysis Report and Forecast Trends (2026-2035)

The global artificial intelligence (AI) in cancer diagnostics market was valued at USD 1.74 Billion in 2025. It is poised to grow at a CAGR of 22.40% during the forecast period of 2026-2035, and reach USD 13.13 Billion by 2035. The market growth is driven by rising cancer prevalence, demand for early detection, and adoption of AI software in hospitals.

Key Market Trends and Insights

• By offerings, the software segment dominated the market, holding a revenue share of over 44% in the historical period.
• Based on cancer type, breast cancer recorded a significant revenue share of more than 19% in the historical period.
• By end user, the hospital segment led the market, accounting for a revenue share of approximately 56% in the historical period.

Market Size and Forecast

• Market Size (2025): USD 1.74 Billion
• Projected Market Size (2035): USD 13.13 Billion
• CAGR (2026-2035): 22.40%

Artificial Intelligence in Cancer Diagnostics Market Overview

Artificial intelligence in cancer diagnostics refers to the application of advanced algorithms to improve cancer detection AI, leveraging imaging biomarkers, histopathology AI, and early detection algorithms for accurate diagnosis. The market is growing due to the increasing adoption of liquid biopsy AI and data-driven tools. The market reached a value of approximately USD 1.74 Billion in 2025, supported by advancements in clinical decision support and diagnostic efficiency. These technologies enhance diagnostic efficiency, enable better patient stratification, and support informed treatment planning, positioning AI as a critical component in improving global cancer care outcomes.

Artificial Intelligence in Cancer Diagnostics Market Growth Drivers

Rising Prevalence of Cancer to Fuel the AI Adoption in the Market

The growing number of people living with cancer is a key factor driving the growth in the market. According to the American Association for Cancer Research (AACR), nearly 20 million people were new cancer cases occurred, while more than 10.3 million people died due to cancer. Increasing cancer prevalence, coupled with the need for early detection, accurate staging, and personalized treatment, is encouraging healthcare providers to deploy AI-powered imaging, predictive analytics, and clinical decision support tools, as well as screening automation, mammography AI, colonoscopy AI, and ctDNA analysis, accelerating market growth and improving diagnostic efficiency during the forecast period.

Artificial Intelligence in Cancer Diagnostics Market Trends

Key trends shaping the market include integration of artificial intelligence in early lung cancer.

Growing Integration of AI in Early Lung Cancer Detection to Enhance the Market Landscape

The market is witnessing a rising demand for early cancer diagnosis and growing adoption of AI-driven radiology tools, which are driving innovation in cancer care. For instance, in January 2026, Bristol Myers Squibb partnered with Microsoft to deploy AI-enabled radiology tools for early lung cancer detection, integrating FDA-cleared algorithms into clinical workflows. This initiative is expected to improve diagnostic accuracy, accelerate treatment initiation, and expand adoption of AI in cancer diagnostics throughout the forecast period.

Artificial Intelligence in Cancer Diagnostics Market Segmentation

Market Breakup by Offerings

• Software
• Hardware
• Services

Market Breakup by Cancer Type

• Breast Cancer
• Lung Cancer
• Brain Cancer
• Colorectal Cancer
• Prostate Cancer
• Others

Market Breakup by End-User

• Hospitals and Clinics
• Diagnostic and Imaging Centers
• Academic and Research Institutes
• Others

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Artificial Intelligence in Cancer Diagnostics Market Share

Breast Cancer to Dominate the Market Segment by Cancer Type

The market, based on the cancer type, includes breast cancer, lung cancer, brain cancer, colorectal cancer, prostate cancer, and others. Among these, breast cancer recorded a significant revenue share of more than 19% in the historical period. According to SEER cancer incidence, globally, about 316,950 new female breast cancer cases were estimated in 2025, underscoring the widespread disease burden and diagnostic demand. This large patient population is driving the adoption of AI diagnostics and clinical decision support tools to improve early detection accuracy and personalized care.

Global Artificial Intelligence in Cancer Diagnostics Market Analysis by Region

The regions included in the market are North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Among these, North America dominated the market in the historical period, accounting for the largest revenue share of over 54%. The region’s leadership is driven by advanced healthcare infrastructure, high adoption of AI diagnostics, and strong presence of major technology and healthcare companies. Integration of clinical decision support, radiology AI, predictive analytics, and multi-omics integration further strengthens market growth and accelerates precision oncology adoption.

Leading Players in Artificial Intelligence (AI) in Cancer Diagnostics Market

The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Aidoc

Aidoc, headquartered in Tel Aviv, Israel, and founded in 2016, develops AI-powered imaging solutions for radiology. Aidoc’s platform leverages radiology AI and deep learning to detect abnormalities, prioritize critical cases, and enhance workflow efficiency. Its solutions support hospitals globally in improving diagnostic accuracy, accelerating clinical decision-making, and integrating clinical decision support tools for the timely detection and management of cancer and other critical conditions.

iCAD, Inc.

iCAD, Inc., headquartered in Nashua, New Hampshire, and founded in 1984, specializes in AI-driven cancer detection and therapy guidance. The company’s portfolio includes AI diagnostics for breast, prostate, and colon cancer, combining imaging software, digital pathology, and advanced analytics to support early detection, accurate diagnosis, and improved patient outcomes. iCAD solutions are widely adopted in hospitals and cancer centers globally.

Microsoft Corporation

Microsoft Corporation supports CancerCenter.AI, a platform founded by Piotr Krajewski to accelerate and improve cancer diagnostics. Built on Microsoft Azure, the platform digitizes pathology scans and leverages AI models to assist physicians in analyzing complex data and collaborating remotely. Pilot studies report increased pathologist productivity, faster diagnoses, and reduced diagnostic errors, highlighting the company’s active role in advancing AI-driven cancer diagnostics.

Cancer Center.ai

Cancer Center.ai, headquartered in Boston, Massachusetts, and founded in 2018, develops AI-powered solutions for cancer diagnostics. Its platform leverages radiology AI and pathology automation to improve diagnostic accuracy, accelerate detection of malignancies, and assist oncologists in clinical decision support. Cancer Center.ai tools are designed to integrate with hospital imaging systems and lab workflows, enhancing efficiency and patient-specific treatment planning across cancer care facilities.

Other key players in the market are Mursla Bio, SkinVision, Kheiron Medical Technologies Limited, Tempus AI, Inc., Paige AI Inc., and Therapixel.

Key Questions Answered in the Artificial Intelligence in Cancer Diagnostics Market

• What was the artificial intelligence in cancer diagnostics market value in 2025?
• What is the artificial intelligence in cancer diagnostics market forecast outlook for 2026-2035?
• What major factors aid the demand for artificial intelligence in cancer diagnostics market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market’s major drivers, opportunities, and restraints?
• What are the major artificial intelligence in cancer diagnostics market trends?
• Which offering is expected to dominate the market segment?
• Which cancer type is projected to lead the market segment?
• Which end user is projected to lead the market segment?
• Who are the key players in the artificial intelligence in cancer diagnostics market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?